Objectives: To describe long-term survival in patients with severe acute respiratory distress syndrome and assess differences in patient characteristics and outcomes among those who receive rescue therapies (prone position ventilation, inhaled nitric oxide, or inhaled epoprostenol) versus conventional treatment.
ach year, more than 175,000 Americans are diagnosed with acute respiratory distress syndrome (ARDS) (1) (2) (3) (4) (5) (6) . Despite management advances such as the use of lung-protective ventilation (7) , ARDS continues to be associated with high morbidity and approximately 30-40% mortality (5) . Patients who develop severe ARDS are typically underrepresented in clinical trials. To our knowledge, there are no long-term outcome studies focused on patients with severe ARDS, including those treated with rescue therapies (6, (8) (9) (10) .
Patients with severe ARDS may develop life-threatening refractory hypoxemia unresponsive to the use of conventional lung-protective ventilation strategies (3) . In clinical practice, as an effort to improve oxygenation in these patients, several different "rescue therapies" are often advocated, including inhaled nitric oxide, inhaled epoprostenol, and prone position ventilation (3, (11) (12) (13) . However, randomized controlled trials conducted to date used rescue therapies as an adjunctive modality to treat ARDS rather than a "last resort" intervention for treatment of critical hypoxemia in rapidly deteriorating patients. Additionally, randomized trials typically did not describe long-term survival as an outcome (14) (15) (16) (17) (18) (19) (20) .
The main objective of this study was to assess the long-term survival in a cohort of patients meeting severe ARDS criteria (5) . Our secondary objectives were to describe characteristics and outcomes of patients receiving a rescue therapy compared with those treated conventionally.
MATERIALS AND METHODS

Ethics Approval and Setting
The University of Washington Institutional Review Board approved this study with a waiver of informed consent. The study setting was Harborview Medical Center (HMC), a 413-bed level 1 trauma hospital located in Seattle, Washington. HMC is affiliated with the University of Washington and is the only level 1 trauma center serving Washington, Alaska, Montana, and Idaho. There are 88 ICU beds distributed among five ICUs (medical/cardiac, trauma/surgical, neurology/neurosurgical, burn, and pediatric).
Population Selection and Study Eligibility Criteria
All medical records for patients 18 years old and older, admitted to a HMC ICU between January 1, 2008, and December 31, 2011, who were mechanically ventilated and met criteria for severe ARDS were evaluated for eligibility. Severe ARDS was defined by the presence of a Pao 2 /Fio 2 ratio less than or equal to 100 mm Hg and the presence of bilateral opacities on chest radiograph not fully explained by effusions, fluid overload, cardiac failure, lung/lobar collapse, or nodules (5) . To reduce study population heterogeneity, only patients who developed a Pao 2 /Fio 2 ratio less than or equal to 100 within 72 hours of ICU admission were included.
To verify radiographic criteria, patients meeting inclusion criteria were linked to the HMC Acute Lung Injury Registry maintained by the on-site ARDS Network study coordinators. Among matched patients, we randomly reviewed 25% of the chest radiographs to ensure greater than 95% agreement. Similarly, radiographs and medical records of subjects identified by Pao 2 /Fio 2 criteria but not included in the ALI registry were manually reviewed. Subjects whose medical records suggested congestive heart failure, fluid overload, or chronic lung disease as an etiology of the radiographic findings were excluded. Patients placed on inhaled nitric oxide, inhaled epoprostenol, or ventilated in the prone position for the treatment of critical hypoxemia were identified within this cohort.
Data Collection
Data were electronically and manually abstracted from the HMC electronic medical record. Demographic and clinical admission variables were collected. The Simplified Acute Physiology Score (SAPS) II was calculated for each patient at ICU admission. For trauma patients, injury severity score (ISS) and abbreviated injury severity (AIS-Head, AIS-Chest) were collected from the HMC Trauma Registry, a database containing comprehensive information for all patients evaluated for traumatic injury at HMC (21) .
Clinical and physiologic variables during the ICU stay were collected and included the study qualifying Pao 2 /Fio 2 ratio, the Pao 2 /Fio 2 ratio nadir within the first 24 and 72 hours of ICU admit, days spent with Fio 2 more than 60%, days of mechanical ventilation, use of vasopressors within the first 24 hours of ICU admission, and use of neuromuscular blockade at any time during the ICU admission. We collected ventilator settings recorded in the electronic medical record closest to 0800 each day; we collected tidal volume (mL/kg), positive end-expiratory pressure (cm H 2 O) delivered, and mode of ventilation closest to 0800 following the study qualifying Pao 2 /Fio 2 ratio. Daily Sequential Organ Failure Assessment (SOFA) scores were calculated for each ICU day following ICU admission. Mean and maximum SOFA scores for the entire ICU stay were also calculated. Additional variables associated with exposure to a rescue therapy were collected and are displayed in Table 1 .
Costs were estimated from the institutional perspective. For each patient, hospital charges were obtained from hospital billing records. Charges were converted to costs by applying the institutional charge-to-cost ratio (0.668 
Endpoints
The primary endpoint was survival up to 3 years using the initial date of ICU admission as the index time. Secondary endpoints included hospital mortality, ICU and hospital length of stay, discharge disposition, and costs.
Statistical Analysis
Baseline demographic characteristics and clinical variables were compared between the patients receiving a rescue therapy and those managed conventionally using a twosample Student t test with assumption of unequal variances for continuous variables and Fisher exact test for categorical variables.
For the primary analysis, we assessed overall survival using the date of first ICU admission as the index date. Censored data were assumed to be independent of survival times. Patients who neither died in the hospital nor were located in the WA State Death Registry and had a primary residential address outside WA State were censored at the time of hospital discharge. Because we only linked with the WA State Death Registry, we considered non-WA State residents to be lost to follow-up.
Survival curves were estimated using the Kaplan-Meier product limit estimator.
We compared overall survival between patients who received a rescue therapy and those treated conventionally using a Cox proportional hazards model adjusted for age, Caucasian race, admission SAPS II, and primary admission diagnosis of sepsis or pneumonia. Hospital mortality was also compared between groups using Cox regression. We estimated the cause-specific hazard ratio for death before discharge, accounting for the competing risk of hospital discharge. The model was adjusted for the same covariates as above. Cumulative incidence curves were used to illustrate in-patient mortality. We chose this approach because we used a competing risk analysis for this endpoint.
For the long-term survival and hospital mortality outcomes, we also conducted a priori planned secondary analyses using propensity score. For each outcome, we fit the following models: 1) a crude unadjusted model, 2) a standard adjusted model as described above, and 3) a propensity score-adjusted model. Propensity scores were obtained using logistic regression to model the odds of receiving 
RESULTS
Study Population
The final cohort included 428 patients with severe ARDS; 62 patients were treated with rescue therapy and 366 were treated conventionally ( Fig. 1) . Demographic and clinical characteristics are displayed in Table 2 . The mean age was 51 years (± 17.7, sd). Roughly 85% of patients were admitted to the medical ICU, with sepsis or pneumonia being the most common primary admission diagnosis. The mean study qualifying Pao 2 /Fio 2 ratio for the entire cohort was 76 mm Hg (± 16).
Compared with patients treated conventionally, patients treated with a rescue therapy were younger (41.7 ± 19.0 yr vs 52.6 ± 17.0 yr, p < 0.01) and more likely to have ARDS secondary to pneumonia or sepsis (p < 0.01). Baseline severity of illness scores and the admission Pao 2 /Fio 2 ratio were not significantly different between groups (Table 2 ). However, the study qualifying Pao 2 /Fio 2 ratio-Pao 2 /Fio 2 ratio less than 100 mm Hg within 72 hours of ICU admission-was significantly different (68 ± 18 mm Hg vs 78 ± 16 mm Hg, rescue compared with conventional therapy, respectively, p < 0.01). The mean tidal volume delivered following the study qualifying Pao 2 /Fio 2 ratio was similar between groups (7.22 ± 1.28 mL/kg vs 6.93 ± 1.35 mL/kg, rescue compared with conventional therapy, respectively, p = 0.10) ( Table 3) . Among patients treated with a rescue therapy, 36 (58%) were treated with an inhaled therapy only, 13 (21%) with prone position ventilation only, and 13 (21%) with a combination of inhaled therapy and prone position ventilation (Table 1) .
Physiologic variables pertinent to degree and onset of hypoxemia are displayed in Table 3 . The lowest Pao 2 /Fio 2 ratios within 24 hours of ICU admit were not different; however, the nadir Pao 2 /Fio 2 ratio within 72 hours was lower in the group exposed to a rescue therapy (54 ± 17 mm Hg vs 69 ± 17 mm Hg; p < 0.01).
Primary Endpoint
The Kaplan-Meier plot for overall survival is shown in Figure 2 . Median follow-up time from ICU admission was 449 days (interquartile range [IQR], 13, 1,138 d). The estimated survival probability at 3 years was 55% (95% CI, 51-61%) for the whole cohort, 51% (95% CI, 40-65%) among those initiated on a rescue therapy, and 56% (95% CI, 51-62%) for patients treated conventionally. In adjusted analyses, overall survival was significantly different between groups ( Table 4 ). Patients treated with a rescue therapy had 56% higher risk of death compared with those treated conventionally (95% CI, 2-137%; p = 0.04).
Results from unadjusted and propensity score analyses showed similar trends. Most deaths occurred during the hospital admission, with few additional deaths observed posthospital discharge. Among those surviving to hospital discharge, the estimated 3-year survival probability posthospital discharge was 85% (95% CI, 80-89%) for the entire cohort.
Secondary Endpoints
Thirty-five percent of the cohort did not survive to hospital discharge. Among patients treated with a rescue therapy, 47% died in the hospital, whereas 32% of patients treated conventionally died before hospital discharge. In the rescue therapy group, the two postdischarge deaths occurred early (day 1 and day 5). Figure 3 shows cumulative incidence curves for hospital mortality. The risk of in-hospital mortality was 68% higher among patients who received a rescue therapy compared with patients managed conventionally (95% CI, 8-162%; p = 0.02) ( Table 4 ).
The median ICU length of stay was 17 days (IQR, 6, 31 d) for rescue therapy patients and 14 days (IQR, 3, 16 d) for patients treated conventionally (p = 0.47); median hospital length of stay was 21 days (IQR, 8, 36 d) and 20 days (IQR, 10, 34 d) for patients treated with and without rescue therapy (p = 0.94). Finally, for patients treated with rescue therapy, mean total hospitalization costs were $218K (sd, 193K) compared with $184K (sd, 168K) for patients not treated with rescue therapies (p = 0.20).
DISCUSSION
In this study focusing on the long-term survival of 428 patients with severe ARDS, we found that while in-hospital mortality was high, survivors to hospital discharge had good 3-year survival. Patients selected for treatment with a rescue therapy were young, had more progressive hypoxemia, and a higher risk of hospital death compared with patients managed conventionally. However, those who survived to hospital discharge also had an equally good chance of living another 3 years. Our data indicate that, unlike the setting of randomized controlled trials, in clinical practice, therapy is not initiated until severe ARDS patients have a declining Pao 2 /Fio 2 ratio, suggesting that physicians are likely to account for the initial response to conventional therapy into their decision to employ rescue treatment (14-16, 18, 19, 23) . There are several possible explanations for the finding that adjusted mortality was higher in the group of patients receiving rescue therapyeither rescue therapies were causing excess death or there was selection bias present with residual unmeasured confounding. To our knowledge, there are no trials that have found inhaled therapies or prone position ventilation to be associated with a higher risk of death (23, 24) . We acknowledge that despite adjusting for potential confounders and secondary propensity-adjusted analyses, unmeasured confounding is still possible. However, the most likely explanation for our findings is the presence of selection bias. At our institution, there is no specific protocol that triggers the initiation of rescue therapy, and this decision is left to the discretion of the attending physician. Therefore, the population selection reflects physician preferences with regard to the type of rescue therapy and the choice of the ARDS population. We used several strategies to minimize selection bias in our study cohort by restricting the inclusion criteria to severe ARDS patients and limiting the eligibility window to the first 72 hours since ARDS onset. In this study, however, we are unable to comment on the independent association between rescue therapies and outcome due to residual confounding and the inability to entirely account for selection bias, two limitations commonly encountered in observational studies.
Context Within Previous Studies
Our study highlights the potential differences between patients selected for rescue therapy treatment in real-world clinical practice and those patients included in randomized, controlled trials. Furthermore, prior negative trials of inhaled nitric oxide therapy and prone position ventilation were not limited to severe ARDS patients (14, 15) . However, Guerin et al (20) recently reported a mortality benefit to early initiation of prone position ventilation in patients with severe ARDS (defined by Pao 2 /Fio 2 < 150 mm Hg). It remains uncertain if patients in our cohort differed in other ways from those included in randomized trials. Rigorous randomized controlled trials investigating the effectiveness of inhaled rescue therapies in patients with severe ARDS, like the recent study of prone position ventilation, are needed (20) .
Limitations
We acknowledge the inherent limitations of retrospective observational data. Additionally, due to the single-center setting, these data may not generalize to institutions with different practices. We acknowledge that at our institution, we do not routinely use airway pressure release ventilation, while highfrequency oscillatory ventilation or extracorporeal membrane oxygenation is not available. Therefore, we cannot comment on these modalities. In this study, we combined three different rescue therapies; therefore, we were unable to determine the association between a given rescue intervention and mortality. Severe ARDS patients, including those placed on a rescue therapy, represent a small proportion of ICU patients, resulting in small sample sizes in this and most prior studies (23, 24) . We acknowledge that a larger sample size could have provided more robust data. For example, our sample size did not provide adequate power for the propensity-adjusted model, although the similar effect sizes between our standard and propensityadjusted models suggest no important difference. Lastly, due to the small sample size, we anticipated that this study would not be powered to detect a difference in costs. Nevertheless, describing clinical practice patterns and long-term outcomes of patients with severe ARDS provides valuable information and can be used to generate hypotheses for future prospective trials.
CONCLUSIONS
Severe ARDS patients have high hospital mortality; however, survivors to hospital discharge have relatively good long-term survival. The subset of severe ARDS patients who have a rapidly declining Pao 2 /Fio 2 ratio and are often identified to be treated with a rescue therapy have even higher hospital mortality. Nonetheless, provided they are discharged alive from the hospital, their long-term survival appears to be comparable to other ARDS survivors. Historically, "rescue" therapies earned this name because they were used as a final effort to improve oxygenation in life-threatening situations (3, 4, 12, 15, 16, 18, 19, (24) (25) (26) . Future prospective studies should investigate the impact timing of initiation of a rescue therapy in patients who develop early onset severe ARDS may have on survival.
